Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.76 USD
Change Today +0.0003 / 0.04%
Volume 67.7K
As of 8:10 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

atossa genetics inc (ATOS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/26/15 - $2.65
52 Week Low
08/26/15 - $0.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ATOSSA GENETICS INC (ATOS)

Related News

No related news articles were found.

atossa genetics inc (ATOS) Related Businessweek News

No Related Businessweek News Found

atossa genetics inc (ATOS) Details

Atossa Genetics Inc. operates as a healthcare company that focuses on the development of a suite of laboratory services, medical devices, and therapeutics for breast cancer in the United States. The company markets nipple aspirate fluid (NAF) cytology tests and pharmacogenomics tests. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator devices that are intended for the collection of NAF for cytological testing at a laboratory. The company is also involved in the development of other devices comprising intraductal microcatheters for the collection of ductal lavage fluid and for the potential administration of a targeted therapeutic, as well as various tools for potential use by breast surgeons. In addition, it owns a specimen bank that contains ductal lavage specimens, and blood and urine specimens. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

27 Employees
Last Reported Date: 03/30/15
Founded in 2009

atossa genetics inc (ATOS) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $500.0K
Chief Financial Officer, General Counsel and ...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2014.

atossa genetics inc (ATOS) Key Developments

Atossa Genetics Inc. Receives Non-Compliance Letter From NASDAQ

On September 28, 2015, Atossa Genetics Inc. received a letter from NASDAQ that the Company was not in compliance with NASDAQ Listing Rule 5550(a)(2) – bid price, because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company has until March 28, 2016 to regain compliance. In the event the Company does not regain compliance by then, the Company may be eligible for additional time if at that time it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and provides written notice to NASDAQ of its intention to cure the deficiency during the second compliance period, including by effecting a reverse stock split, if necessary. The letter also states that the NASDAQ staff will provide written notification that the Company has regained compliance if the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days. The NASDAQ notice has no immediate effect on the listing or trading of Atossa’s common stock on the NASDAQ Stock Market. The Company intends to actively monitor the bid price for its common stock between now and March 28, 2016, and will consider available options to resolve the deficiency and regain compliance with the minimum bid price requirement.

Atossa Genetics Inc. Announces FDA Acceptance of its Investigational New Drug Application to Begin Phase II Clinical Trial of Fulvestrant for the Treatment of D

Atossa Genetics Inc. announced that the U.S. Food and Drug Administration has accepted the Company's Investigational New Drug (IND) application for a clinical trial of Fulvestrant in patients with Ductal Carcinoma in Situ (DCIS) or breast cancer. Acceptance of the IND by the FDA enables Atossa to now move forward with an open-label, non-randomized pharmacokinetic and safety study of Fulvestrant in women with DCIS or breast cancer who are scheduled for mastectomy. Patients will be treated with either intramuscular Fulvestrant or intraductal instillation of Fulvestrant utilizing Atossa's patented intraductal microcatheter device.

Atossa Genetics Receives Approval to Begin Clinical Study of ForeCYTE Breast Aspirator Device in Israel

Atossa Genetics reported that it has received institutional review board approval to begin a clinical study in Israel to evaluate its ForeCYTE breast aspirator device in the collection of Nipple Aspirate Fluid (NAF) in women aged 30-55. The company will start study enrollment in September 2015 and 70 women will be enrolled in three centres in Israel. This is the first study outside the US to use the company's ForeCYTE device as well as its first sponsored study that will submit a subset of specimens (those from known carriers of the BRCA germline mutation) to contemporary molecular tests in addition to cytology (cellular evaluation of cells for evidence of ductal hyperplasia or atypia). The study is seeking to obtain data that will help in the development and validation of a molecular marker panel intended to help guide surgeons and women, particularly the subset of participants who carry the BRCA germline mutation, in the decision to consider prophylactic bilateral radical mastectomy.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATOS:US $0.76 USD +0.0003

ATOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biocept Inc $2.34 USD +0.0533
Illumina Inc $145.81 USD -17.36
View Industry Companies

Industry Analysis


Industry Average

Valuation ATOS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.2x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATOSSA GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at